Analysis of the Effect of Non-Invasive Positive Pressure Ventilation in Emergency Treatment of Severe Bronchial Asthma with Respiratory Failure

Abstract

Objective: This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation (NIPPV) in patients with severe bronchial asthma combined with respiratory failure. Methods: 90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group (NIPPV-assisted treatment) and the control group. The differences between the two groups were compared in terms of total effective rate of treatment, days of clinical symptom disappearance, days of hospitalization, lung function indexes, incidence of adverse reactions, and quality of life. Results: Patients in the experimental group had a significantly higher total effective rate of treatment (97.78%) than the control group (75.56%). In terms of pulmonary function indexes, patients in the experimental group showed significant improvement after treatment, especially the increase in forced expiratory volume and forced vital capacity, while these improvements were not as obvious in the control group. In addition, the incidence of adverse reactions was significantly lower in the experimental group than in the control group, suggesting that the application of NIPPV is relatively safe. Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment. Conclusion: This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure. NIPPV can improve lung function, reduce the incidence of adverse effects, increase the overall effectiveness of the treatment, and contribute to the improvement of patients’ quality of life. Therefore, NIPPV should be regarded as an effective and safe treatment in clinical management, especially in patients with severe bronchial asthma combined with respiratory failure, where its application has potential clinical significance.